Forest/Gedeon line up FDA meetings to pursue cariprazine
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Gedeon Richter are "working with the US FDA to resolve the complete response letter for cariprazine in schizophrenia and bipolar mania," Forest has told Scrip. The update came with news that the companies have obtained positive top-line results from a Phase IIb trial evaluating the investigational antipsychotic in patients with bipolar depression.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.